摘要
目的探讨治疗前中性粒细胞与淋巴细胞比值(NLR)与表皮生长因子受体(EGFR)突变晚期肺腺癌患者靶向治疗预后的关系。方法回顾性分析110例EGFR突变晚期肺腺癌患者的临床资料。根据血常规结果计算NLR值,以NLR值3.5为最佳截断值,分为高NLR(≥3.5)组和低NLR(<3.5)组。比较高NLR组和低NLR组晚期肺腺癌患者的临床特征及2组患者靶向治疗后无进展生存期(PFS)和总生存时间(OS)的差异,分析影响患者PFS和OS的因素。结果低NLR组患者PFS和OS均较高NLR组高,差异有统计学意义(P<0.05);COX回归分析结果显示,NLR水平是PFS和OS的影响因素。结论高NLR是EGFR突变晚期肺腺癌患者靶向治疗预后的影响因素,提示预后不良,可以预测靶向治疗的疗效。
Objective To investigate the relationship between neutrophil-to-lymphocyte ratio(NLR)at baseline and the prognosis of targeted therapy in patients with advanced EGFR-mutated lung adenocarcinoma.Methods The clinical data of 110 patients with advanced EGFR-mutated lung adenocarcinoma were retrospectively analyzed.According to the results of blood routine test,the NLR was calculated(absolute value of neutrophils/absolute value of lymphocytes).Taking 3.5 as the cutoff value of NLR,and the patients were divided into high NLR(≥3.5)group and low NLR(<3.5)group.The differences in the clinical features,progression-free survival(PFS)and overall survival(OS)after targeted therapy were compared between the high and low NLR groups,and the factors influencing PFS and OS were analyzed.Results PFS and OS in the low NLR group were longer than those in the high NLR group,with statistically significant differences(P<0.05).COX regression analysis showed that NLR level was the influencing factor of PFS and OS.Conclusion High NLR is an influencing factor for the prognosis of targeted therapy in patients with advanced EGFR-mutated lung adenocarcinoma,suggesting a poor prognosis and predicting the efficacy of targeted therapy.
作者
贾林梓
毛光华
单彬彬
王军
冯爱萍
Jia Linzi;Mao Guanghua;Shan Binbin;Wang Jun;Feng Aiping(Department of Biotherapy,Shanxi Provincial Cancer Hospital,Taiyuan 030013,China;不详)
出处
《中国药物与临床》
CAS
2020年第18期2984-2987,共4页
Chinese Remedies & Clinics
关键词
肺肿瘤
受体
表皮生长因子
靶向治疗
NLR
Lung neoplasms
Receptor,epidermal growth factor
Targeted therapy
NLR
